AI assistant
ARROWHEAD PHARMACEUTICALS, INC. — Director's Dealing 2015
Jan 7, 2015
31071_dirs_2015-01-07_ea891c03-7f9e-4316-8f12-4b35865cc60e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ARROWHEAD RESEARCH CORP (ARWR)
CIK: 0000879407
Period of Report: 2015-01-05
Reporting Person: Lewis David L. (Chief Scientific Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2015-01-05 | Common Stock | M | 15000 | $2.01 | Acquired | 15000 | Direct |
| 2015-01-05 | Common Stock | S | 15000 | $8.0069 | Disposed | 0 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2015-01-05 | Stock Option (right to buy) | $2.01 | M | 15000 | Disposed | 2023-05-06 | Common Stock (15000) | Direct |
Footnotes
F1: Represents the weighted average price at which shares were sold within a range between $8.00 and $8.03. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F2: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F3: Represents first vesting date. Option vests over four years from date of grant.